Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026 Positive ...
In this Q&A, Beowolff Capital CEO Andrew Wolff explains why he believes the future of the art market lies in transparency, data and A.I.-powered collaboration. He outlines how integrating ...
Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...
CALGARY, AB / ACCESS Newswire / November 12, 2025 / Primary Hydrogen Corp. (TSXV:HDRO)(FRA:83W0)(OTCQB:HNATF) ("Primary" or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback